Skip to main content
Industry News
PET sheds light on efficacy of ketamine in depression
6/5/2020

More than 70% of individuals with difficult-to-treat depression who received ketamine achieved treatment response, and PET scans associated ketamine treatment with an increased amount of serotonin 1B receptors, according to a study in Translational Psychiatry. Dr. Johan Lundberg said ketamine is "very rapid-acting" but may also result in addiction, and using the serotonin 1B receptor as treatment target may lead to production of depression therapies without adverse effects.

Full Story: